(11-248) Evaluation of Treatment-Related Adverse Events and Discontinuation Rates in Triple Negative Breast Cancer Patients Treated with KEYNOTE-522 Regimen at a Community Cancer Center.
Wednesday, December 10, 2025
12:30 PM - 1:30 PM
Location: Bayside A, Level 1
Residency Program: Holy Name Medical Center Residency Program Type: PGY1 (Pharmacy) Residency Program Location: New Jersey
